



RECEIPT

Attorney's Docket No.: 003829.P003

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James Goodwin, et al.

Application No.: 09/273,238

Filed: March 19, 1999

For: OPTIMIZATIONS FOR TUNNELING
BETWEEN A BUS AND A NETWORK

)
) Examiner: Not Assigned
)
) Art Unit No.: 2731
)
)
)
)
)
)
)
)
)

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

REQUEST TO CORRECT ERRORS IN FILING RECEIPT

Sir:

Applicants respectfully request that the inventors City/State addresses be listed as follows :

- 1) James Goodwin, Santa Clara, California
- 2) Joseph Meza, Milpitas, California
- 3) David Zalatimo, Menlo Park, California

**FIRST CLASS CERTIFICATE OF MAILING
UNDER 37 C.F.R. § 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail with sufficient postage in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on 4-21-99.

Sharon M. Osofsky
Name of Person Mailing Correspondence

Sharon M. Osofsky
Signature


4-21-99
Date

Applicants believe no fee is due for this request to correct errors in the Filing Receipt. However, if any additional fee is required, please charge Deposit Account No. 02-2666.

Respectfully submitted,

BLAKELY SOKOLOFF TAYLOR & ZAFMAN LLP

Dated: 4/20, 1999



Michael J. Mallie
Attorney for Applicants
Reg. No. 36,591

12400 Wilshire Boulevard
Seventh Floor
Los Angeles, CA 90025-1026
(408) 720-8598

APR 27 1999

FILING RECEIPT
PATENT & TRADEMARK OFFICE

ENTERED

APR 12 1999

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/273,238	03/19/99	2731	\$3,322.00	003829.P003	15	80	22

MICHAEL J MALLIE
BLAKELEY SOKOLOFF TAYLOR & ZAFMAN
12400 WILSHIRE BOULEVARD
7TH FLOOR
LOS ANGELES CA 90025Filmed Corp.
MTM

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the date presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

JAMES GOODWIN; RESIDENCE NOT PROVIDED; JOSEPH MEZA;
RESIDENCE NOT PROVIDED; DAVID ZALATIMO; RESIDENCE
NOT PROVIDED.IF REQUIRED, FOREIGN FILING LICENSE GRANTED 04/07/99
TITLE
OPTIMIZATIONS FOR TUNNELLING BETWEEN A BUS AND A NETWORK

PRELIMINARY CLASS: 370

RECEIVED

APR 14 1999

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN
LOS ANGELES

DATA ENTRY BY: THOMAS, SHEILA

TEAM: 06 DATE: 04/07/99

COPIED FROM 08747122 ON 12/16/2010

(see reverse)



FIRST CLASS CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

on

4-22-99

Date of Deposit

Sharon M. Osofsky

Name of Person Mailing Correspondence

Sharon M. Osofsky

Signature

4-22-99

Date

Serial/Patent No. 09/273,238	Filing/Issue Date 3/19/99
Client: Filanet Corporation	
Title: OPTIMIZATIONS FOR TUNNELING BETWEEN A BUS AND A NETWORK NETWORK	
BSTZ File No. 003829.P003	Att/Secty Initials: MJM/smo
Date Mailed: 4-21-99	Docket Due Date: *****
The following has been received in the U.S. Patent & Trademark Office on the date stamped hereon:	
<input type="checkbox"/> Amendment/Response (____ pgs.)	<input type="checkbox"/> Express Mail No. _____
<input type="checkbox"/> Appeal Brief (____ pgs.) (in triplicate)	<input type="checkbox"/> Month(s) Extension of Time _____
<input type="checkbox"/> Application - Utility (____ pgs., with cover and abstract)	<input type="checkbox"/> Information Disclosure Statement & PTO 449 (____ pgs.)
<input type="checkbox"/> Application - Rule 1.53(b) Continuation (____ pgs.)	<input type="checkbox"/> Issue Fee Transmittal _____
<input type="checkbox"/> Application - Rule 1.53(b) Divisional (____ pgs.)	<input type="checkbox"/> Notice of Appeal _____
<input type="checkbox"/> Application - Rule 1.53(b) CIP (____ pgs.)	<input type="checkbox"/> Petition for Extension of Time _____
<input type="checkbox"/> Application - Rule 1.53(d) CPA Transmittal (____ pgs.)	<input type="checkbox"/> Petition for _____
<input type="checkbox"/> Application - Design (____ pgs.)	<input checked="" type="checkbox"/> Postcard _____
<input type="checkbox"/> Application - PCT (____ pgs.)	<input type="checkbox"/> Power of Attorney (____ pgs.)
<input type="checkbox"/> Application - Provisional (____ pgs.)	<input type="checkbox"/> Preliminary Amendment (____ pgs.)
<input type="checkbox"/> Assignment and Cover Sheet	<input type="checkbox"/> Reply Brief (____ pgs.)
<input checked="" type="checkbox"/> Certificate of Mailing	<input type="checkbox"/> Response to Notice of Missing Parts
<input type="checkbox"/> Declaration & POA (____ pgs.)	<input type="checkbox"/> Small Entity Declaration for Indep. Inventor/Small Business
<input type="checkbox"/> Disclosure Docs & Orig & Copy of Invention Signed Letter (____ pgs.)	<input type="checkbox"/> Transmittal Letter, in duplicate
<input type="checkbox"/> Drawings: _____ # of sheets includes _____ figures	<input type="checkbox"/> Fee Transmittal, in duplicate
<input checked="" type="checkbox"/> Other: Request to Correct Errors in Filing Receipt	
Copy of Received Filing Receipt	

39. 5,561,053, Oct. 1, 1996, Method for selecting high-expressing host cells; Craig W. Hawley, 435/69.1, 172.3, 320.1, 536/23.2 :IMAGE AVAILABLE:
40. 5,559,208, Sep. 24, 1996, Anti-obesity proteins; Margret B. Basinski, et al., 530/317, 324, 350 :IMAGE AVAILABLE:
41. 5,554,727, Sep. 10, 1996, Anti-obesity proteins; Margret B. Basinski, et al., 530/324, 350 :IMAGE AVAILABLE:
42. 5,552,524, Sep. 3, 1996, Anti-obesity proteins; Margret B. Basinski, et al., 530/324, 350 :IMAGE AVAILABLE:
43. 5,552,523, Sep. 3, 1996, Anti-obesity proteins; Margret B. Basinski, et al., 530/324, 350 :IMAGE AVAILABLE:
44. 5,552,522, Sep. 3, 1996, Anti-obesity proteins; Richard D. DiMarchi, et al., 530/324 :IMAGE AVAILABLE:
45. 5,552,284, Sep. 3, 1996, Detection of interleukin-8 receptors by nucleic acid hybridization; James Lee, et al., 435/6; 536/24.3, 24.31 :IMAGE AVAILABLE:
46. 5,543,503, Aug. 6, 1996, Antibodies to human IL-8 type A receptor; Anan Chuntharapai, et al., 530/388.22; 424/85.2; 530/351, 389.2 :IMAGE AVAILABLE:
47. 5,541,287, Jul. 30, 1996, Pretargeting methods and compounds; Eric K. Yau, et al., 530/317, 323, 330, 331, 332, 345 :IMAGE AVAILABLE:
48. 5,534,615, Jul. 9, 1996, Cardiac hypertrophy factor and uses therefor; Joffre Baker, et al., 530/350; 424/569, 570; 530/380 :IMAGE AVAILABLE:
49. 5,532,336, Jul. 2, 1996, Anti-obesity proteins; Richard D. DiMarchi, et al., 530/324, 350 :IMAGE AVAILABLE:
50. 5,525,705, Jun. 11, 1996, Anti-obesity proteins; Richard D. DiMarchi, et al., 530/324 :IMAGE AVAILABLE:
51. 5,521,283, May 28, 1996, Anti-obesity proteins; Richard D. DiMarchi, et al., 530/324 :IMAGE AVAILABLE:
52. 5,514,582, May 7, 1996, Recombinant DNA encoding hybrid immunoglobulins; Daniel J. Capon, et al., 435/252.3, 69.7, 320.1; 536/23.5, 23.52, 23.53 :IMAGE AVAILABLE:
53. 5,489,508, Feb. 6, 1996, Therapy and diagnosis of conditions related to telomere length and/or telomerase activity; Michael D. West, et al., 435/6, 15, 91.1, 91.5; 436/64; 536/24.33; 935/77 :IMAGE AVAILABLE:
54. 5,484,891, Jan. 16, 1996, Selectin ligands; Laurence A. Lasky, et al., 530/387.3; 435/7.2; 530/350, 395 :IMAGE AVAILABLE:
55. 5,474,901, Dec. 12, 1995, Antibodies to human carboxypeptidase B and methods of use thereof; Dennis T. Drayna, et al., 435/7.4, 7.92; 436/161, 518, 824; 530/387.1 :IMAGE AVAILABLE:
56. 5,455,165, Oct. 3, 1995, Expression vector encoding hybrid immunoglobulins; Daniel J. Capon, et al., 435/69.7, 252.3, 320.1; 536/23.4 :IMAGE AVAILABLE:
57. 5,451,660, Sep. 19, 1995, Method for purifying polypeptides; Stuart E. Builder, et al., 530/344, 300, 324, 350, 351, 399, 413 :IMAGE AVAILABLE:

58. 5,446,024, 29, 1995, Purification of insulin-like growth factor; Stuart E. Builder, et al., 514/12; 530/303, 399, 407 :IMAGE AVAILABLE:
59. 5,440,021, Aug. 8, 1995, Antibodies to human IL-8 type B receptor; Anan Chuntharapai, et al., 530/388.22, 388.23, 389.1, 389.2 :IMAGE AVAILABLE:
60. 5,428,130, Jun. 27, 1995, Hybrid immunoglobulins; Daniel J. Capon, et al., 530/350; 435/69.7; 530/387.1; 536/23.4 :IMAGE AVAILABLE:
61. 5,407,810, Apr. 18, 1995, Aqueous multiple-phase isolation of polypeptide; Stuart Builder, et al., 435/69.1, 804; 530/399, 412, 422, 808 :IMAGE AVAILABLE:
62. 5,367,060, Nov. 22, 1994, Structure, production and use of heregulin; Richard L. Vandlen, et al., 530/399, 350 :IMAGE AVAILABLE:
63. 5,364,934, Nov. 15, 1994, Plasma carboxypeptidase; Dennis T. Drayna, et al., 536/23.2; 435/252.3, 320.1, 369 :IMAGE AVAILABLE:
64. 5,352,587, Oct. 4, 1994, Compositions and methods for the synthesis of natriuretic protein receptor B and methods of use; Ming-Shi Chang, et al., 514/12; 435/69.1, 172.1, 252.3, 252.33, 254.21, 320.1, 358, 365, 369; 530/350 :IMAGE AVAILABLE:
65. 5,346,991, Sep. 13, 1994, Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders; Soumitra Roy, et al., 530/350; 435/172.3; 530/381, 829 :IMAGE AVAILABLE:
66. 5,336,603, Aug. 9, 1994, CD4 adheson variants; Daniel J. Capon, et al., 435/69.7; 424/134.1; 435/252.3, 320.1; 530/350, 387.3; 536/23.4 :IMAGE AVAILABLE:
67. 5,328,891, Jul. 12, 1994, **Insulin**-like growth factor binding protein and pharmaceutical compositions; Robert C. Baxter, et al., 514/2, 12; 530/350, 402 :IMAGE AVAILABLE:
68. 5,326,699, Jul. 5, 1994, Serum-free medium for culturing animal cells; Hisashi Torishima, et al., 435/384, 387, 391, 405, 406, 408 :IMAGE AVAILABLE:
69. 5,304,640, Apr. 19, 1994, DNA sequence encoding a selectin ligand; Laurence A. Lasky, et al., 536/23.5; 435/69.1, 172.3, 320.1, 369 :IMAGE AVAILABLE:
70. 5,304,603, Apr. 19, 1994, Leydig cell stimulator; C. Yan Cheng, et al., 514/12, 15, 21; 530/397, 398, 399, 416, 417; 935/60 :IMAGE AVAILABLE:
71. 5,286,654, Feb. 15, 1994, Detection and purification of activin polypeptide; Edward T. Cox, et al., 436/501, 536; 530/388.22, 395, 413 :IMAGE AVAILABLE:
72. 5,258,287, Nov. 2, 1993, DNA encoding and methods of production of **insulin**-like growth factor binding protein BP53; Robert C. Baxter, et al., 435/69.1, 6, 69.8, 252.3, 254.11, 254.2, 320.1, 365, 369; 536/23.5 :IMAGE AVAILABLE:
73. 5,229,365, Jul. 20, 1993, Endocrine cell stimulation by neurotrophic agents; Michel Polak, et al., 514/12, 8, 21 :IMAGE AVAILABLE:
74. 5,225,538, Jul. 6, 1993, Lymphocyte homing receptor/immunoglobulin fusion proteins; Daniel J. Capon, et al., 530/387.3; 424/134.1; 435/69.7;

530/388.73 :IMAGE AVAILABLE:

75. 5,223,408, Jun. 29, 1993, Method for making variant secreted proteins with altered properties; David V. Goeddel, et al., 435/69.3, 69.4, 69.52, 69.6, 69.7, 172.3, 189, 195, 215, 216, 226 :IMAGE AVAILABLE:
76. 5,216,131, Jun. 1, 1993, Lymphocyte homing receptors; Laurence A. Lasky, et al., 530/350, 300, 324 :IMAGE AVAILABLE:
77. 5,216,126, Jun. 1, 1993, Receptor polypeptides and their production and uses; Edward T. Cox, et al., 530/350, 388.22, 389.1 :IMAGE AVAILABLE:
78. 5,206,161, Apr. 27, 1993, Human plasma carboxypeptidase B; Dennis T. Drayna, et al., 435/212, 69.1 :IMAGE AVAILABLE:
79. 5,190,756, Mar. 2, 1993, Methods and materials for expression of human plasminogen variant; Francis J. Castellino, et al., 424/94.64; 435/216, 217, 226; 514/822 :IMAGE AVAILABLE:
80. 5,168,050, Dec. 1, 1992, Mammalian expression of the bone morphogenetic protein-2B using BMP2A/BMP2B fusion; R. Glenn Hammonds, Jr., et al., 435/69.1, 320.1, 360, 369; 530/350 :IMAGE AVAILABLE:
81. 5,166,190, Nov. 24, 1992, Method for increasing fertility in males; Jennie P. Mather, et al., 514/8, 12; 530/397, 399 :IMAGE AVAILABLE:
82. 5,122,469, Jun. 16, 1992, Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins; Jennie P. Mather, et al., 435/383 :IMAGE AVAILABLE:
83. 5,116,964, May 26, 1992, Hybrid immunoglobulins; Daniel J. Capon, et al., 536/23.5; 424/134.1; 435/69.7, 252.3, 320.1; 530/350, 387.3; 536/23.51, 23.53 :IMAGE AVAILABLE:
84. 5,098,833, Mar. 24, 1992, DNA sequence encoding a functional domain of a lymphocyte homing receptor; Laurence A. Lasky, et al., 435/69.1, 252.3, 320.1, 361; 530/350; 536/23.51 :IMAGE AVAILABLE:
85. 5,087,572, Feb. 11, 1992, DNA encoding human plasminogen modified at the cleavage site; Francis J. Castellino, et al., 435/359, 217, 252.3, 320.1; 536/23.51 :IMAGE AVAILABLE:
86. 5,063,157, Nov. 5, 1991, Serum-free culture medium for mammalian cells; Hubertus Stockinger, 435/387, 6, 389, 391, 406, 408 :IMAGE AVAILABLE:
87. 5,057,417, Oct. 15, 1991, Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein; R. Glenn Hammonds, et al., 435/69.1, 172.3, 252.33, 317.1, 360, 369; 536/23.51; 935/11, 70, 73 :IMAGE AVAILABLE:
88. 5,024,939, Jun. 18, 1991, Transient expression system for producing recombinant protein; Cornelia M. Gorman, 435/69.1, 172.3 :IMAGE AVAILABLE:
89. 4,960,700, Oct. 2, 1990, Compositions and methods for the synthesis and assay of a mammalian enkephalinase; Bernard Malfroy-Camine, et al., 435/172.3, 212, 219, 252.33, 358, 369 :IMAGE AVAILABLE:
90. 4,929,542, May 29, 1990, In vitro screening test for mutagenicity and genotoxicity during spermatogenesis; Michael S. Risley, 435/2, 4, 29, 243, 244, 379, 406, 809 :IMAGE AVAILABLE: